RHHBY - Morgan Stanley sees Fed rate cut fueling biotech stock performance
2024-04-07 13:31:00 ET
More on Merck, SPDR S&P Biotech ETF, etc.
- Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade)
- Merck: Better Times Ahead On Approvals And Outlook
- Merck's Future Brightens With Winrevair's Blockbuster Potential
- Merck to test lung cancer combo therapy in late-stage trial
- Bristol Myers wins label expansion for anemia therapy in EU